

### **Overview of Cancer Services in Kent and Medway**

The 2011 Cancer strategy contained a list of information which would prove useful to members of the public as well as providers and commissioners.

The following report sets out an overview of Cancer Services in Kent and Medway as requested by the Committee and specifically addresses the questions raised under section 1.

Question 2a is addressed in the accompanying document Cancer Peer Review Report 2011 - 2012

Kent & Medway Cancer Network South Zone Peer Review Team June 2012.

#### **This report contains:**

- An overall summary diagram of the structure of the Network and compliances
- A national benchmarking summary of MDT and Network measures
- An overall Network Report which contains:
  - Contextual information about the Network
  - An Executive Summary
  - Progress against Improving Outcomes Guidance
- A summary of compliance of MDT measures per Trust



Provider (s) ➔	East Kent			West Kent & Medway			Specialist Centre/Supranetwork Providers								
Cancer Type & Process ↓	East Kent Ashford	East Kent Canterbury	East Kent Margate	Maidstone & Tunbridge Wells Maidstone & Pembury <i>MTW have now merged all of their Disease Site Specific MDTs</i>	Dartford	Medway	Guy's	King's College Hospital	Royal Marsden	St Georges	University College Hospital	RNOH	Charring Cross	East Grinstead	St John's (GKT)
<b>Haematology</b>															
Unit level MDT and treatments		✓		✓	✓	✓		✓							
Centre level MDT & treatments (e.g. Bone Marrow Transplant) <i>Whole of K&amp;M</i>								✓							
<b>Sarcoma *</b>															
Bone MDT, surgery & chemotherapy <i>Whole of KM</i>									✓		✓	✓			
Soft tissue surgery & chemotherapy <i>Whole of K&amp;M</i>									✓		✓				
<b>Skin</b>															
Centre level MDTs & treatments		✓				✓									
Specialist level treatments							✓								✓
Unit level treatment	✓	✓	✓	✓		✓*								✓*	✓
<b>Thyroid</b>															
Unit level MDT		✓		✓											
Surgery		✓		✓		✓									
<b>Upper GI</b>															
Unit level MDT		✓ (linked)		✓	✓	✓									
Centre level MDT for oesophago-gastric <i>Whole of K&amp;M</i>				✓											
Oesophago-gastric surgery <i>Whole of K&amp;M</i>				✓											
Centre level MDT for pancreas <i>Whole of K&amp;M</i>								✓							
Pancreatic surgery <i>Whole of K&amp;M</i>								✓							
<b>Urology</b>															
Unit level MDT and routine surgery		✓		✓		✓ Linked									
Penile cancer MDT & surgery										✓					
Testicular cancer MDT									✓						
Centre level MDT		✓				✓									
Radical prostatectomy		✓				✓									
Total cystectomy		✓				✓									
Complex nephrectomy							✓								

(\*These Skin MDTs function as a "single" MDT, QVH relies of MFT for joint Unit/Centre status)

**1. b) Whether each team has core members from all the relevant disciplines -**

**1. c) Whether the team has a Clinical Nurse Specialist**

All team except those detailed in the following table have core members from all the relevant disciplines and include a Clinical Nurse Specialist

**Kent & Medway MDT Core Membership by disease group**

<b>EAST KENT BREAST MDT</b>	<b>2012/2013 Peer Review Cycle Information</b>
<b>Kent &amp; Canterbury Hospital</b>	Not a complete team:- No named Histopathologist, only one Radiologist attends the MDT, Oncologist has limited cover
<b>Queen Elizabeth The Queen Mother Hospital</b>	Not a complete team:- No 2nd Histopathologist, 2nd Radiologist
<b>Brain and Central Nervous system MDT</b>	
<b>Maidstone Hospital</b>	Not a complete team:- No Occupational Therapist, Speech & Language Therapist Specialist Palliative Care representation, Physiotherapist, Keyworker. No formal CNS cover (just informal). does not meet attendance requirements, limited Oncologist cover, Research nurse needs to attend the MDT.

**1 d) The number of patients by equality characteristic diagnosed/treated in the previous year**

New cancers diagnosed – Jan to Dec 2011: 11,372

Male	6009
Female	5363
Age	
<= 18	15
19 – 40	328
41 – 60	2252
61 – 80	6361
80+	2187
Unknown	229

**1 e) compliance with waiting times standards - Cancer Waiting Times**  
**Dashboard - Kent and Medway 2011 summary**

Percentages	Operational Standard	Tolerance	January 2011	February 2011	March 2011	April 2011	May 2011	June 2011
<b>14 Days</b>	<b>93</b>	<b>+2%</b>	94.7	<b>97.1</b>	<b>96.3</b>	<b>95.7</b>	94.8	94.4
<b>14 Days Breast Symptoms</b>	<b>93</b>	<b>+2%</b>	95.2	95.1	94.8	94.1	93.6	94.0
<b>31 Days First Treatment by Tumour</b>	<b>96</b>	<b>+1%</b>	97.9	96.0	98.2	97.8	97.5	99.2
<b>31 Days Subsequent Treatment by Tumour</b>	<b>98</b>	<b>+1%</b>	98.7	99.1	98.6	<b>97.8</b>	98.9	98.1
<b>31 Days Subsequent Drug Treatment</b>	<b>98</b>	<b>+1%</b>	100.0	100.0	99.4	98.6	100.0	<b>97.9</b>
<b>31 Days Subsequent Radiotherapy</b>	-	-	98.0	100.0	98.9	98.2	99.3	99.7
<b>31 Days Subsequent Surgery</b>	<b>94</b>	<b>+1%</b>	98.6	96.4	96.7	95.9	97.6	94.5
<b>62 Days Standard</b>	<b>85</b>	<b>+3%</b>	85.6	<b>84.3</b>	89.1	90.2	86.3	88.9
<b>62 Days Screening</b>	-	-	95.3	91.9	92.1	100.0	97.1	95.6
<b>62 Days Upgrade</b>	-	-	100.0	81.2	82.6	71.4	90.5	90.9

Percentages	Operational Standard	Tolerance	July 2011	August 2011	September 2011	October 2011	November 2011	December 2011
<b>14 Days</b>	<b>93</b>	<b>+2%</b>	95.9	<b>95.7</b>	95.3	96.0	97.0	97.4
<b>14 Days Breast Symptoms</b>	<b>93</b>	<b>+2%</b>	94.8	95.1	94.1	94.9	94.2	94.2
<b>31 Days First Treatment by Tumour</b>	<b>96</b>	<b>+1%</b>	98.7	98.7	98.5	98.4	98.3	98.7
<b>31 Days Subsequent Treatment by Tumour</b>	<b>98</b>	<b>+1%</b>	99.8	99.2	99.5	99.4	99.7	99.7
<b>31 Days Subsequent Drug Treatment</b>	<b>98</b>	<b>+1%</b>	99.3	100.0	99.3	100.0	100.0	100.0
<b>31 Days Subsequent Radiotherapy</b>	-	-	100.0	99.7	100.0	100.0	100.0	100.0
<b>31 Days Subsequent Surgery</b>	<b>94</b>	<b>+1%</b>	100.0	97.0	98.6	98.2	98.7	98.6
<b>62 Days Standard</b>	<b>85</b>	<b>+3%</b>	88.9	89.8	88.3	85.8	87.3	90.3
<b>62 Days Screening</b>	-	-	88.6	96.7	97.8	91.4	100.0	89.4
<b>62 Days Upgrade</b>	-	-	100.0	83.3	100.0	82.4	85.7	81.0

Dark grey	Above Target
Light grey	Within Tolerance of Target
White on grey	Below Target

**1 f) Compliance with peer review measures.**

Please see attached document Cancer Peer Review Report 2011 – 2012

**1 g) major resection rates –**

I am unable to supply this data – the provider organisations will submit this data in April for national upload. Once the quality of the data has been reviewed these figures will be made available.

However the numbers of Patients with surgery as their first definitive treatment:

7562 patients have a first definitive treatment recorded

4232 have surgery as first definitive treatment = 55.96%

**1 h) Mortality within 30 days of treatment**

I am unable to supply this data at this point in time – This data is beginning to be collected by the provider organisations – they are not mandated to submit against this until 2014 and at this time remains incomplete.

**2 a) is addressed in the accompanying document Cancer Peer Review Report 2011 – 2012**

**2 b) is addressed in the attached document: KMCN Closure letter 2013 01**